BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
about
Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cellsNKG2D ligands as therapeutic targetsContrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer CellsImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancerRegulation of ligands for the NKG2D activating receptor.Recognition of tumors by the innate immune system and natural killer cells.IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer.ULBP6/RAET1L is an additional human NKG2D ligand.The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cellsValproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligandRegulation of ligands for the activating receptor NKG2D.Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaImmunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.NKG2D ligands in tumor immunity.NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting.Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy CellsAn integrated view of the regulation of NKG2D ligands.MICA Expression Is Regulated by Cell Adhesion and Contact in a FAK/Src-Dependent Manner.Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activityNatural Killer Group 2, Member D/NKG2D Ligands in Hematopoietic Cell Transplantation.Effect of NKG2D ligand expression on host immune responsesNatural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.Novel immune modulators used in hematology: impact on NK cellsRegulation of self-ligands for activating natural killer cell receptors.Advances in NKG2D ligand recognition and responses by NK cells.Molecular Bases for the Regulation of NKG2D Ligands in Cancer.Does the immune system naturally protect against cancer?Exploiting natural killer group 2D receptors for CAR T-cell therapy.MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA.
P2860
Q24654966-D5CBAF87-A884-441E-A307-2D4CCD864284Q27014888-6E330039-C38E-458F-9C00-D2CFADFA22D4Q28550076-CB89F57C-EF6E-42C7-A7C4-9AFE4592060DQ33593877-C8686E2C-38AE-4033-ADCC-61153B4817BFQ33815894-6EA44F43-B0C3-448E-92DC-8744E90B7A6FQ34321457-A58949C5-531F-40E5-983B-34424A4B1CF3Q34496462-5B2C4943-798E-49BF-B28F-90E1674E4C87Q34625042-9AABD611-36A9-4820-8F85-1E10EF06AE62Q34815702-480BED3A-911D-4B5D-8787-72CD3D818C12Q34995302-00353323-3593-47E9-8A1F-7FF67AB98661Q34995891-EDC93133-7C73-47BA-AF3D-2ADDCEC60F9BQ36278732-E0112764-1D9D-408F-9749-5A92C7DEEC84Q36388560-DE48203D-4CB8-4141-BC86-CEF5EDC13569Q36520715-9ACA4CB8-1DC7-49D0-B3B7-80313458CFFAQ36813516-7728C8F5-DFD2-4F5D-9234-A15B336B84B2Q36872056-45FFA31F-423B-4B90-89A1-07B360BC5893Q36915675-058A6E4C-30A4-41A8-BC54-583E00D82BE7Q37059387-106CF670-C4D0-4FB7-90FB-9B6AE502D83FQ37077413-26C56023-8AB5-4FC9-B399-7DB0661FF7E9Q37101325-3880746E-A670-425D-9AE9-C05FC6C7D9BDQ37287179-E73397FF-A995-4B00-89F1-81BBF769170BQ37424326-3CB8C467-2F72-4AC4-879A-E5B8FF022A3AQ37559284-CEAC0626-1BA4-42F1-BBB3-DE2872A40A7DQ37582005-D5602967-4419-4DA8-A339-B6FA83F53452Q37592694-4B9DF675-0C17-44F1-8F1A-8311494C45A4Q37644845-B2363A9F-C8D1-4721-BF28-FD2928D348B5Q37721591-CA25B730-1AEF-40F1-BF42-C8F9D525A638Q37764003-D8A6FF77-4A22-4BBE-B2F2-5BC2A392F2E3Q37779043-8A1FBC53-99CC-42FE-8FCC-7F7DBA010FFFQ37951937-88C509DF-A414-46F8-A2C1-02FA1B23F719Q38035301-0E05403C-D92B-463A-B773-2349CC2B2617Q38073760-47E77762-E9D0-453D-AB6E-FEF292EC72A3Q38108820-440388E1-0B29-4312-9EE1-72BCAF03000CQ38180339-FB16FF03-1647-44E8-B941-BAC7D36E61EBQ38202957-0A140A23-F11A-4155-9756-A8DC606CD715Q38214640-05B0C88A-E985-4128-B536-9F830E910BD6Q38671184-5ECE1260-5868-4405-8DB4-C0F4B1C10503Q38789090-219B3226-4A5E-40CF-9643-0B895CA63D18Q38839145-1B4DA808-EA3B-4A98-A498-F31301C488A4Q39117541-C38D7F53-882E-4C2A-87AA-E9526EE64DF3
P2860
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
BCR/ABL oncogene directly cont ...... chronic myelogenous leukemia.
@en
type
label
BCR/ABL oncogene directly cont ...... chronic myelogenous leukemia.
@en
prefLabel
BCR/ABL oncogene directly cont ...... chronic myelogenous leukemia.
@en
P2093
P50
P1476
BCR/ABL oncogene directly cont ...... chronic myelogenous leukemia.
@en
P2093
Antoine Toubert
Dominique Charron
François-Xavier Mahon
Jean-Michel Cayuela
Manuel Brun
Nicolas Boissel
Philippe Le Bouteiller
Philippe Rousselot
Ryad Tamouza
Vannary Tieng
P304
P356
10.4049/JIMMUNOL.176.8.5108
P407
P577
2006-04-01T00:00:00Z